Press Release Submission and Distribution Services | Press Release Power

Researched Possibilities of Sildenafil

Mon, 23 May 2022 05:22:58 +0600

Press Release Content: Pharmacyonline.co.uk pharmacists report that Sildenafil, the male-enhancing drug, acts to promote increased circulation 30-60 minutes after administration. A single dose is necessary to achieve the desired effect, though sexual arousal is required to achieve proper physical arousal.

Sildenafil poses minimal, mild side effects. Diarrhea, dizziness, headaches, and muscle pain are some of the limited side effects that may occur when taking Sildenafil for erectile dysfunction. Priapism, or an erection lasting longer than 4 hours, is a rare side effect that should be treated immediately by an emergency medical provider.

Sildenafil can be taken continuously as a lifestyle-enhancing drug, though it should not be taken more than 4 times a week. When taking Sildenafil, it is recommended to only take one dose within a 24-hour period.

Sildenafil may not always work when administered initially. Dosage, food, and alcohol consumption may all impede the ability of Sildenafil to enter the bloodstream and achieve the desired physical effect. It may take up to 8 doses for Sildenafil to work properly. Speaking to a medical provider can address lingering concerns regarding the limited effects of taking Sildenafil before switching to an alternative erectile dysfunction medication, as other factors, including diet or underlying medical problems, maybe the cause of concern.

Patients suffering from heart conditions should consult their physician before taking Sildenafil, as it is possible to enlarge the heart blood vessels while taking the drug. Patients suffering from other medical conditions should also consult a healthcare provider before starting a Sildenafil regimen. Patients are advised to always read the instructions before taking Sildenafil to ensure proper compliance.

Pharmacy online is a leading provider of a host of generic drugs, including Sildenafil. Pharmacy online allows patients access to a comprehensive drug selection at affordable prices with rapid delivery times. Pharmacy online also makes available information on various conditions, including erectile dysfunction, and the online assessment feature makes it easier to find the right medication and understand its proper usage. Pharmacy online now makes it possible to acquire Sildenafil more easily and enjoy the lifestyle-enhancing benefits this drug offers.

For more information on Sildenafil or other drug options, patients are advised to consult the pharmacy online's webpage at https://www.pharmacyonline.co.uk/. Further inquiries can also be directed to 0141 952 5918. For those looking to enjoy a highly touted, lifestyle-enhancing product, Pharmacy online's recent offering of Sildenafil makes this popular drug even more accessible to the general public.

https://www.pharmacyonline.co.uk

Phone - +44 0141 952 5918

Email - hello@pharmacyonline.co.uk

INDUSTRIAL WASTEWATER TREATMENT AND HOW DOES IT WORK?

Thu, 07 Apr 2022 12:09:07 +0600

The Industrial wastewater treatment process is the combination of physical, chemical, and biological treatments that are applied to wastewater to reduce pollution and prevent contaminants from being discharged into the environment or waterways. The most common industrial water treatment solution is the activated sludge process.

Industrial water treatment is a process used for is a variety of applications with simple and complex, effective, low-cost, and compact systems to handle various water purification and separation needs. Industrial water treatment is needed since if unclean water is utilized in the production process then the unwanted substances can have a negative effect on product quality and if water is used in production developments, impurities can directly affect on your product quality.

Our team will help you find a way to maintain their reputation while still complying with regional regulations and requirements.

They also reduce operational costs by reducing energy consumption, eliminating the need for expensive filters that would clog quickly, and reducing the need for more maintenance staff.

Industrial water treatment provides a clean and safe environment to work in. It also helps keep the water clean and safe for the people who properly use it.

The industrial water treatment process is used to clean up the water that is used for industrial processes, such as cooling towers and boilers. The process includes many steps, from screening to coagulation, sedimentation, and filtration.

Water Treatment plants are an important part of any manufacturing plant. The system cleans up the water that is used for industrial processes, such as cooling towers and boilers.

Industrial water treatment is a specialized segment of the water treatment industry that produces processes, equipment, and chemicals to remove or reduce the impact of contaminants on the water in industrial applications.

Aqua Filsep Inc. is one of the Best Water Treatment Plant Solutions providers in India for pharmaceutical companies and other Water Treatment industry.

Our Water Treatment systems are supreme for all industries with specific needs and are available for standard solutions with custom designs.

AquaFilsep is a water treatment service provider in India. It provides water purification and treatment services to a wide range of industrial customers globally.

Global Intravenous Solutions Market Growth, Trends, Share, COVID-19 Analysis and Forecast 2021-2028

Mon, 06 Dec 2021 10:52:28 +0600

The global Intravenous Solutions Market research report is the well-analyzed solution for the decision-makers and academicians who are seeking a detailed analysis in terms of both qualitative as well as quantitative, for the historic period and for the upcoming years forecast. The research report encompasses the industry overview along with the forthcoming threats and supporting factors that will drive or hamper the market growth and provide opportunities in the near future.

DOWNLOAD FREE SAMPLE STUDY PDF (INCLUDING FULL TOC, TABLE & FIGURES) @ https://www.amecoresearch.com/sample/274377

The Intravenous Solutions Market is finely segmented by considering the most important and responsive aspects of the respective market. Additionally, the segments are well analyzed for every geographical region including United States, European Union, China, Japan, India, Korea, and Southeast Asia. The major countries are covered with detailed information.

Most importantly, the impact of the COVID-19 pandemic that has disrupted the global market in terms of the supply chain, money flow, and overall market economics is comprehensively covered by including qualitative and quantitative approaches in the final report.

MARKET SEGMENTATION

The global Intravenous Solutions market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Intravenous Solutions market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.

CUSTOMIZED REQUIREMENTS? NEED ANY HELP? PLEASE EMAIL US @ sales@amecoresearch.com

Apart from the segmentation, the market research report encompasses established strategic tools (Value Chain Analysis, Supply Channel Analysis, Porter’s five forces model, and others) that help individuals in easy understanding and analyzing the overall information in a more comprehensive and systematic manner.

KEY PLAYERS

The Intravenous Solutions key manufacturers in this market include:
Baxter
Kelun Group
Fresenius Kabi
Otsuka
ICU Medical
Fresenius Kabi
JW Life Science
B. Braun Melsungen

Most of the top major players are being covered in the research report along with their product offerings, revenue contribution, regional presence, strategic developments, and business strength.

FEW SIGNIFICANT POINTS FROM TABLE OF CONTENT:

Global Intravenous Solutions Market Research Report 2021-2028

https://www.amecoresearch.com/global-intravenous-solutions-market-forecast-2028/toc/274377

KEY QUESTIONS ANSWERED IN THE REPORT

The report addresses key questions concerning the market evolution and overarching trends shaping global market growth. Some of the key questions answered in the report include-

– What is the overall structure of the market?

– What was the historical value and what is the forecasted value of the market?

– What are the key product level trends in the market?

– What are the market level trends in the market?

– Which of the market players are leading and what are their key differential strategies to retain their stronghold?

– Which are the most lucrative regions in the market space?

THE FINAL REPORT WILL COVER THE IMPACT ANALYSIS OF COVID-19, DOWNLOAD FULL STUDY REPORT@ https://www.amecoresearch.com/buy/274377

AMECO RESEARCH IS PART OF ACUMEN RESEARCH AND CONSULTING.

Contact:

Email: sales@amecoresearch.com| +1 407 915 4157

Follow Us:-

LinkedIn: https://www.linkedin.com/company/ameco-research

Twitter: https://twitter.com/AmecoResearch

Global Digital Therapeutics Market valued at $2.2bn, poised to transform the Digital Health Industry

Fri, 03 Sep 2021 10:20:12 +0600

The worldwide digital therapeutics market fixed at $ 2.2 billion (2020) is set to acquire force. The following period of development liable to be driven by developing pharma-advanced remedial collusions, developing focal point of digital therapeutics organizations on emotional wellness, mental conditions and intellectual debilitations, continuously further developing repayment situation, ideal subsidizing climate and solid pipeline of advanced therapeutics items.

Changing clinical conventions, need to reduce expenses, development and broad reception of innovation explicitly in the space of computerized reasoning, profound learning and wellbeing checking utilizing wearables is progressively changing pharma services and has made ready for another class of therapeutics known as advanced therapeutics (DTx).

Digital therapeutics are items (programming programs) that convey proof based helpful intercessions to patients to forestall, oversee, or treat a clinical issue or illness. They are utilized independently or in blend with meds, clinical gadgets or different treatments to streamline patient consideration and wellbeing results.

Advanced therapeutics is ready to alter the pharma care industry. It discovers use across a reach applications like Diabetes, Chronic Respiratory Disorders, Musculoskeletal Disorders, Smoking Cessation, Cardiovascular Diseases, CNS Disorders, Obesity and Others. It offers massive incentive for various partners. Key partners, for example, FDA, HCPs, Payers, and Patients are presently expanding accepting advanced therapeutics as a type of treatment.

Explore More on Digital Therapeutics Market @ https://www.medgadget.com/2021/08/digital-therapeutics-market-size-at-2-2bn-poised-to-revolutionize-the-pharma-digital-health-industry-innovative-business-models-favourable-reimbursement-robust-product-pipelines-set-to-impact-be.html

The accompanying advantages for the partners across the pharma services range affirms the potential for digital therapeutics.

Patients: On-request and simple admittance to clinically-approved treatments, treatment and care. Customized and adaptable consideration for some constant conditions.

Suppliers: Digital therapeutics can be utilized as a monotherapy or working together with different treatments to streamline patient consideration and results. Doctors/parental figures can uphold patients distantly and screen their reaction to treatment without an office visit accordingly prompting a lower cost of care. It likewise gives them admittance to novel treatment alternatives.

Payers: Improved clinical and wellbeing results, illness anticipation and decrease in generally speaking clinical expenses.

Companies: Pharma organizations could profit from information gathered by digital therapeutics organizations about understanding and their condition. Through advanced therapeutics, pharma organizations can work on the adequacy of their current treatments. advanced therapeutics can likewise be utilized in clinical exploration to speed the medication endorsement measure. Model – Bayer, Otsuka, and Sanofi's interests into computerized restorative new companies.

The digital therapeutics market has additionally stood out of a few financial backers and they also are adjusted on the worth of advanced therapeutics.

Consider the accompanying realities that has made digital therapeutics so fundable.

Information Collection Capabilities: Digital therapeutics can gather a gigantic measure of patient wellbeing information which can be utilized for customized treatment of patients, empower information driven consideration for suppliers and further develop wellbeing results

Successful Tool for Chronic Conditions: Chronic conditions keep on expanding in commonness and has crippling impact on the pharma services framework. Advanced therapeutics has arisen as a powerful apparatus for persistent sickness the board

digital therapeutics Supported by Clinical Evidence: Since advanced therapeutics items are upheld by clinical information, there is clinical proof of it being viable

Take into account Unmet Needs: Digital therapeutics can possibly address numerous persistent conditions which have neglected necessities, for example, treatment-safe gloom and narcotic fixation .

Solid Positive Outlook: The assessed market capability of digital therapeutics offsets the obstacles.

Through regional analysis of the worldwide digital therapeutics market covering U.S., Europe (Germany, Italy, France, Spain, UK, and Rest of Europe), Asia-Pacific (India, China, Japan, Australia, New Zealand, Singapore and Rest of Asia-Pacific) and Rest of the World (Latin America, Middle-East and Africa) proposes that U.S. is probably going to proceed with its strength in the following 10 years. Rising pervasiveness of persistent infections, good government strategies and awards, developing mindfulness with respect to advanced therapeutics and its advantages and all around created medical services framework is set to sling the U.S. advanced therapeutics market. Help of advanced therapeutics drove by Pharmacy Benefit Managers (PBMs) in the U.S. is additionally expected to fuel its reception.

For Detailed Insights, Get in Touch @ https://meditechinsights.com

Bay Life Compounding Success Story: From Traditional Pharmacy to Online Pharmacy Specializing in Assisted Living

Fri, 21 May 2021 07:27:34 +0600

Bay Life Compounding has transitioned from serving as a traditional offline pharmacy that offers assisted living services to an online pharmacy in recent years. The move has resulted in immense success as evidenced by the growth the company has enjoyed in the years following it.

The locally-owned company has been servicing seniors and functioning as a licensed compounding pharmacy in the Tampa Bay area for a good number of years now. Currently, it has four active branches in the said area, a clear sign of growth and expansion spurred by the company’s decision to render its services online.

What started as a regular pharmacy slowly developed to a compounding pharmacy that proudly labels itself as a one-stop shop for everyone’s medication needs. Its connection to that rapidly growing field of modern pharmacy is well-founded and developed.

As of this writing, it already provides compounding services in numerous medical disciplines, not least of which are dermatology, pain management, hormone replacement therapy, veterinary care, sterile compounding, and weight management, to cite a few. Most of its services, including those that focus on assisted living, have received overwhelmingly positive feedback.

Innately connected to its growth is the decision to function as an online pharmacy. Owner, (owner’s name), has this to say about Bay Life Compounding’s remarkable success story, “We expected positive things to happen when we made the move, but we never imagined it would be to the degree that we are currently experiencing.

“We owe it as much to our clients who believed in our services and saw first-hand the difference that they made. That being said, it’s also important to acknowledge the fact that we would not have gained such a wider audience if we continued to serve as an offline pharmacy. Even so, it seemed already set in stone since the pandemic factored into our decision a lot as well.

Like many locally-owned companies out there, we had very humble beginnings characterized by a lot of struggles. Nonetheless, we persevered and became a well-known pharmacy in Tampa Bay, thanks primarily to our more affordable options and our patient-centric approach to compounding medicines.

Our experience and deep knowledge of the pharmaceutical industry in the US served as our compass and helped us set our goals and philosophies. For one, it made us adopt a policy of guaranteeing the safety of our products by removing unnecessary yet possibly harmful ingredients from our medications. Also, we never compromise on quality and ethical standards.

Trust in our industry carries a lot of weight. And without a doubt, we would not have gained such a reputation without prioritizing and maintaining it. It’s one of the keys to our success.”

“We maintained this stance even when we decided to cater more to assisted living services. It’s not at all a coincidence that our rise happened after we made that move as well. The assisted living industry is rapidly growing, and with this growth comes an equally increasing demand for medications for the elderly, magnified, more or less, by the pandemic.

On the whole, we’re glad that our growth directly aids in curbing its effects and in keeping public health at it best. We eagerly expect the myriad ways we can traverse from here on.”

While Bay Life Compounding still maintains its four locations, all of its products and services are now available online, and finished medications or those that have already been formulated and sold at the online pharmacy can be delivered to a patient’s place of residence.

System Analytic Launches a Major New Update to Its Superfly Platform - a Powerful 'Out of the Box' End-to-End HCP/KOL Management Tool

Sat, 01 May 2021 15:45:25 +0600

System Analytic, a leading provider of KOL-focused digital tools and services for pharmaceutical companies, announced the launch of a new generation of its Superfly End-2-End KOL/HCP management platform.

Pharmaceutical commercial and medical teams typically engage with thousands of HCPs every year across a range of collaborative projects. Superfly is a straight-out-of-the-box, fully customisable KOL & HCP management solution that's engineered to support the entire end-to-end process, from contract-to-pay.

Pharmaceutical teams encounter a set of unique challenges when it comes to HCP and KOL end-to-end management - event initiation, event approval, needs assessment, budget management, FMV management, Caps management, HCP approval, digital contracting, MSA management, tax document management, payment cycle management, and more. Each of these challenges, in turn, usually involves a series of sub-tasks involving individuals from multiple teams within the organisation e.g. business, medical, legal, financing, contracting, and audit.

Pharma often has to resort to the use of multiple disparate systems to complete all the different tasks that are required to ensure a compliant and successful HCP and KOL collaboration process. The result is often inefficient, costly, and open to compliance errors.

The new updated Superfly platform enables Pharma to solve all the above challenges through a single integrated workflow and comes with several enhancements and innovations including: full mobile/tablet optimisation, configurable dashboards based on user role, better integration with engagement plans for individual HCPs, and improved reporting across the board.

Easy to implement, easy-to-use, and easy to configure, the intuitive workflows and configuration options of Superfly E2E will help pharma and biotech clients to solve the pains of end-to-end HCP management so that they can start planning, managing, and tracking their work with Experts across the entire contract-to-pay process in a highly efficient and compliant manner.

Dr Sanjay Singhvi, a Director at System Analytic, said, "Every day we hear from our clients about the pain of HCP end-to-end process in Pharma. And nothing quite brings us more joy than solving those pains, every day."

-ENDS-

About System Analytic:

Our visionary digital tools and world-class services help our clients to identify, understand, and engage with the most important people in their world. As a company, this is all we think about, this is all we do - and we do it with an analytical intensity and brilliance unmatched by anyone else.

We combine the best of medicine with the best of technology to create innovative offerings that are characterized by transparency, collaboration, and trust. That's why the world's leading pharma companies and the world's leading physicians entrust us with their confidence - and we do everything in our power to justify the faith they place in us.

System Analytic is a WPP company.

www.systemanalytic.com

Source URL - https://www.newswire.com/news/system-analytic-launches-a-major-new-update-to-its-superfly-platform-a-21377612

MEI Pharma Announces the Retirement of Chief Medical Officer Robert Mass and Promotion of Richard Ghalie to Chief Medical Officer

Sat, 01 May 2021 08:57:57 +0600

MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the retirement of Robert Mass, M.D., MEI's chief medical officer. Dr. Mass joined the company in 2010 and will retire on May 3, 2021, after which he will continue to serve as a strategic advisor to the company. The Company also announced that Richard Ghalie, M.D., MEI's senior vice president, clinical development, has been promoted to chief medical officer.

"Bob's contributions to MEI over his more than ten years at the company have been invaluable across our drug candidate pipeline, particularly in guiding the strategy and broad clinical development program for zandelisib, which will best be measured by the benefit these programs may ultimately provide to patients. I want to thank Bob for his dedication to MEI and his friendship over these past 10 years.

We wish him the very best in his retirement and look forward to continued interaction through his advisory role," said Daniel P. Gold, Ph.D., president and chief executive officer of MEI Pharma. "I also welcome Richard stepping into his role as our new chief medical officer, a role for which he is very well suited, as evidenced by the significant progress in our zandelisib program under Richard's guidance and its progress with our partners at Kyowa Kirin towards zandelisib's planned new drug application for consideration by FDA for approval under the accelerated approval pathway."

Dr. Mass commented, "Working with Dan and the entire MEI team over the past decade has been deeply rewarding and this is an ideal time for my transition. We have generated important clinical data with zandelisib indicating its potential as a best-in-class PI3K-delta specific inhibitor and launched a comprehensive clinical development plan, including monotherapy and combinations with other therapies, in low grade lymphomas and additional indications. Our initial registration study, TIDAL, has recently reached its planned recruitment target for its primary efficacy population and we have a plan in place for a future NDA submission for consideration by FDA under the accelerated approval pathway. I am confident that Richard and the extended MEI team will continue to execute our strategy to bring zandelisib to patients across a broad spectrum of B-cell malignancies and look to continued involvement in an advisory role."

Dr. Ghalie was appointed as senior vice president, clinical development in March 2016. He is a hematologist and oncologist with more than 25 years of drug development experience at public and private companies. Dr. Ghalie has held several executive positions in the pharmaceutical industry and has led medical teams that successfully filed NDAs and MAAs resulting in the approval of four new indications. Dr. Ghalie holds a medical degree from the French School of Medicine in Lebanon, a master's degree from the University Paris XI and an MBA from the University of Washington in Seattle. He has authored or co-authored more than 125 manuscripts, book chapters and scientific publications.

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma's portfolio of drug candidates contains four clinical-stage assets, including zandelisib, currently in an ongoing Phase 2 clinical trial which may support accelerated approval marketing applications with the U.S. Food and Drug Administration. Each of MEI Pharma's pipeline candidates leverages a different mechanism of action with the objective of developing therapeutic options that are: (1) differentiated, (2) address unmet medical needs and (3) deliver improved benefit to patients either as standalone treatments or in combination with other therapeutic options. For more information, please visit www.meipharma.com and follow us on Twitter and LinkedIn.

Forward-Looking Statements

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical studies and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; the impact of the COVID-19 pandemic on our industry and individual companies, including on our counterparties, the supply chain, the execution of our clinical development programs, our access to financing and the allocation of government resources; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

Source URL - https://www.prnewswire.com/news-releases/mei-pharma-announces-the-retirement-of-chief-medical-officer-robert-mass-and-promotion-of-richard-ghalie-to-chief-medical-officer-301280990.html

Are Internet Pharmacies as Safe as Brick-and-Mortar Ones?

Fri, 30 Apr 2021 12:05:56 +0600

Americans have been hearing about forthcoming changes to the pharmaceutical industry that will work to lower the prices for prescription drugs for years now. There's been little in the way of progress there. There are a host of reasons why prescription drugs are often very expensive in America, but the primary one is that the USA is the only country that has a system allowing drug manufacturers to set prices as freely as they please. These ongoing high prices have U.S. residents increasingly looking to online pharmacies in Canada, like Canada Drugs Direct, to have their prescriptions filled for less.

It's natural for people looking into this alternative to ask if Internet pharmacies are safe, and are they as safe as brick-and-mortar ones found in their community. The short answer is that yes, they are safe, and the reason why most online pharmacies are safe is because ones in the USA and every online pharmacy in Canada are going to be required to adhere to operating guidelines. Ones that are put in place by the US FDA and Health Canada.

Both countries have measures in place to ensure compliance, and this includes inspections to ensure they have the same good operating practices as storefront pharmacies. However, what can the average individual do to be assured they're going to receive safe, pure, and quality products when ordering drugs online from Canada or getting them from a U.S. online pharmacy?

For starters, you should be able to determine that the pharmacy meets these three criteria:

a valid prescription from a licensed doctor is required before prescriptions are filled

a physical address and telephone number is clearly listed on the pharmacy's site

speaking or consulting with a licensed pharmacist is available through the online pharmacy

Plus, there are two good online resources you can use to check if a pharmacy is safe or reputable. If you're considering an online pharmacy in the USA, use the US FDA's own database of licensed online pharmacies by State. If you've decided to order your medication online from Canada, verify the pharmacy with PharmacyChecker or use the CIPA (Canadian International Pharmacy) list of accredited pharmacies in Canada.

About the Company

Canada Drugs Direct is a Canadian online pharmacy that is among those recommended for Americans who shop at a pharmacy in Canada to save money on medications. It is able to source medications in a way that allows for the best prices on Rx drugs from Canada. All orders require a prescription and are dispensed by a licensed pharmacist, in the same as any pharmacy in America. Pay less for medication ordered online from Canada.

Contact Canada Drugs Direct:

https://www.canadadrugsdirect.com/

Toll Free: 1-888-904-8467

info@canadadrugsdirect.com

Source URL - https://www.newswire.com/news/are-internet-pharmacies-as-safe-as-brick-and-mortar-ones-21378020

Hikma announces US FDA approval of KLOXXADOTM (naloxone hydrochloride) nasal spray 8mg

Fri, 30 Apr 2021 10:09:25 +0600

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces the approval of KLOXXADOTM (naloxone hydrochloride) nasal spray 8mg, by the US Food and Drug Administration (FDA) for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients.

KLOXXADOTM contains twice as much naloxone per spray as Narcan® Nasal Spray 4mg in a ready-to-use nasal spray to reverse the effects of opioid overdose, providing an important new treatment option in addressing the opioid epidemic.

Drug overdose, including most commonly opioid overdose, has been described as the "leading cause of accidental death" in the US today1 – a situation that has been exacerbated by the COVID-19 pandemic2. According to health organizations, widely prescribing and distributing naloxone may play a vital role in the fight against opioid overdose3. With the increasing prevalence of illicitly manufactured synthetic opioids, a higher dose of naloxone may be required to revive a patient4.

In a survey of community organizations to which Narcan® Nasal Spray 4mg had been distributed, 34% of attempted reversals used two or more doses5. Additionally, a separate study published in 2019 found that the percent of overdose-related EMS calls in the US requiring multiple doses of naloxone during 2013-2016 had increased to 21%, representing a 43% increase over those four years6.

"The approval of KLOXXADOTM is an important step in providing patients, friends and family members – as well as the public health community – with an important new option for treating opioid overdose," said Brian Hoffmann, President, Hikma Generics. "As an experienced provider of addiction therapy treatments and a leading producer of nasal sprays in the US, we are pleased to leverage our capabilities to deliver an important new tool in the fight against opioid overdose."

Hikma expects KLOXXADOTM to be available in the second half of 2021.

About Naloxone

Naloxone hydrochloride is an opioid antagonist that antagonises opioid effects by competing for the same receptor sites. Administration of naloxone hydrochloride reverses the effects of opioids, including respiratory depression, sedation and hypotension. Naloxone has a long history of safe use as the standard of care for reversing opioid overdoses7.

KLOXXADOTM is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients. KLOXXADOTM is not a substitute for emergency medical care. KLOXXADOTM is intended for immediate administration as emergency therapy in settings where opioids may be present.

KLOXXADOTM is a trademark of Hikma Pharmaceuticals USA Inc.

NARCAN® is a registered trademark of ADAPT Pharma Operations Limited.

Enquiries

Hikma Pharmaceuticals PLC

Susan Ringdal

EVP, Strategic Planning and Global Affairs

+44 (0)20 7399 2760/ +44 7776 477050

uk-investors@hikma.uk.com

Steve Weiss

David Belian

US Communications and Public Affairs

+1 732 720 2830/ +1 732 788 8279

+1 732 720 2814/+1 848 254 4875

uscommunications@hikma.com

About Hikma

(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P and BBB-/stable Fitch)

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

KLOXXADOTM (naloxone hydrochloride) Nasal Spray Important Safety Information

CONTRAINDICATIONS

Hypersensitivity to naloxone hydrochloride or to any of the other ingredients in KLOXXADOTM

WARNINGS AND PRECAUTIONS

Risk of Recurrent Respiratory and Central Nervous System Depression

Seek emergency assistance immediately after administration of the first dose and keep the patient under continued surveillance. The duration of action of most opioids may exceed that of KLOXXADO, resulting in a return of respiratory and/or central nervous system depression after an initial improvement in symptoms. Administer additional doses as necessary if the patient is not adequately responding or responds and then relapses back into respiratory depression.

Risk of Limited Efficacy With Partial Agonists or Mixed Agonist/Antagonists

Reversal of respiratory depression by partial agonists or mixed agonist/antagonists may be incomplete. Larger or repeat doses of naloxone hydrochloride may be required.

Precipitation of Severe Opioid Withdrawal

Use in patients who are opioid-dependent may precipitate opioid withdrawal characterized by body aches, diarrhea, tachycardia, fever, runny nose, sneezing, piloerection, sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, abdominal cramps, weakness and increased blood pressure. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated and may include convulsion, excessive crying and hyperactive reflexes. Monitor the patient for the development of the signs and symptoms of opioid withdrawal. For more information about management of opioid withdrawal, see the full Prescribing Information.

Abrupt reversal of opioid effects in persons who were physically dependent on opioids has precipitated an acute withdrawal syndrome. In some patients, there was aggressive behavior upon abrupt reversal of an opioid overdose.

Abrupt postoperative reversal of opioid depression after using naloxone hydrochloride may result in nausea, vomiting, sweating, tremulousness, tachycardia, hypotension, hypertension, seizures, ventricular tachycardia and fibrillation, pulmonary edema and cardiac arrest. Death, coma and encephalopathy have been reported as sequelae of these events. These events have primarily occurred in patients who had pre-existing cardiovascular disorders or received other drugs that may have similar adverse cardiovascular effects. Monitor these patients closely in an appropriate healthcare setting.

ADVERSE REACTIONS

In two pharmacokinetic studies, a total of 47 healthy adult volunteers were exposed to a single dose of KLOXXADO, one spray in one nostril.

The following adverse reactions were reported in two subjects each: abdominal pain, asthenia, dizziness, headache, nasal discomfort, and presyncope.

Signs of nasal inflammation and nasal congestion were observed

Serious adverse reactions reported: none

The following most frequently reported events (in decreasing frequency) have been identified primarily during post-approval use of naloxone hydrochloride: withdrawal syndrome, vomiting, nonresponsiveness to stimuli, drug ineffective, agitation, somnolence, and loss of consciousness.

USE IN SPECIFIC POPULATIONS

Pregnancy

Naloxone may precipitate opioid withdrawal in the pregnant woman and fetus. Careful monitoring is needed until the fetus and mother are stabilized.

Infants

In situations where the primary concern is for infants at risk for opioid overdose, consider the availability of alternate naloxone-containing products.

For more information, please see the full Prescribing Information and Patient Information, which you can find in the full press release published on our website at https://www.hikma.com/newsroom/#pageRS=1.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit https://www.fda.gov/medwatch or call 1-800-FDA-1088.

Distributed by: Hikma Specialty USA Inc., Berkeley Heights, NJ 07922

Document Identification Number: WW40054

1 https://pubmed.ncbi.nlm.nih.gov/29262202/

2 https://www.wsj.com/articles/the-opioid-crisis-already-serious-has-intensified-during-coronavirus-pandemic-11599557401?mod=article_inline

3 https://emergency.cdc.gov/han/2020/han00438.asp

4 https://emergency.cdc.gov/han/2020/han00438.asp

5 2016 FDA Advisory Committee on the Most Appropriate Dose or Doses of Naloxone to Reverse the Effects of Life-threatening Opioid Overdose in the Community Settings, Page 149: https://www.fda.gov/media/100409/download

6 2019 Geiger et. al., Substance Abuse: https://www.tandfonline.com/doi/abs/10.1080/08897077.2019.1640832

7 https://www.fda.gov/consumers/consumer-updates/having-naloxone-hand-can-save-life-during-opioid-overdose

Source URL - https://www.prnewswire.com/news-releases/hikma-announces-us-fda-approval-of-kloxxadotm-naloxone-hydrochloride-nasal-spray-8mg-301280855.html

Photocure Publishes its 2020 ESG Report

Fri, 30 Apr 2021 09:37:53 +0600

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of its sustainability (ESG) report for 2020, renewing its commitment to transparency, corporate governance principles, sustainability and business ethics.

As a result of this commitment, Photocure has also recently become a signatory of the United Nations Global Compact.

Reflecting on ESG matters in 2020, Dan Schneider, President and CEO of Photocure said:

"At Photocure, our mission is to deliver transformative solutions to improve the lives of bladder cancer patients. We seek to do so in a responsible way. We will continue to build a high-performance corporate culture based on a foundation that values diversity, equality, and inclusion, and is respectful and operates with the highest level of integrity.

We are proud of our unique technology, making bladder cancer cells glow bright pink, which to date has helped treat over 500,000 patients worldwide. In 2020, the company had to deal with business volatility due to the global Covid-19 pandemic and I am pleased with how we managed through these unprecedented times and proud of our employees for adapting to changing working conditions and continuing to serve our patients and customers.

The most important impact is our positive contribution to patients' lives, and the economies and the societies in which we operate. This impact comes with a responsibility and requires that we comply with laws, regulations and guidelines, that we listen to our stakeholders and constantly strive to deliver quality products through responsible business operations. Being part of the solution rather than the problem is anchored in our DNA as we strive to give bladder cancer patients access to care in a sustainable way, while working to create value for our shareholders. Becoming signatory of the United Nations Global Compact anchors our commitment to doing things the right way, officially implementing the Ten Principles and holding ourselves and business partners accountable.

This year, we deliver Photocure's second sustainability report according to the GRI Standards core option. We are following up on the targets and progress for each material topic, as defined in last year's ESG report and we continue to set goals for how to improve our work in the future. I hope this report will provide valuable insights for our stakeholders and the essential information about our response to the sustainability challenges and opportunities for our business and society." Schneider concludes.

The full ESG report is attached and available at https://www.photocure.com/investor/reports-and-presentations/.

Note to editors:

All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA

This press release may contain product details and information which are not valid, or a product is not accessible, in your country. Please be aware that Photocure does not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

About Bladder Cancer

Bladder cancer ranks as the seventh most common cancer worldwide with 1 720 000 prevalent cases (5-year prevalence rate)1a, 573 000 new cases and more than 200 000 deaths annually in 2020.1b

Approx. 75% of all bladder cancer cases occur in men.1 It has a high recurrence rate with an average of 61% in year one and 78% over five years.2 Bladder cancer has the highest lifetime treatment costs per patient of all cancers.3

Bladder cancer is a costly, potentially progressive disease for which patients have to undergo multiple cystoscopies due to the high risk of recurrence. There is an urgent need to improve both the diagnosis and the management of bladder cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of invasion in the bladder wall. NMIBC remains in the inner layer of cells lining the bladder. These cancers are the most common (75%) of all BC cases and include the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has grown into deeper layers of the bladder wall. These cancers, including subtypes T2, T3 and T4, are more likely to spread and are harder to treat.4

1 Globocan. a) 5-year prevalence / b) incidence/mortality by population. Available at: https://gco.iarc.fr/today, accessed [April 2021].2 Babjuk M, et al. Eur Urol. 2019; 76(5): 639-6573 Sievert KD et al. World J Urol 2009;27:295–3004 Bladder Cancer. American Cancer Society. https://www.cancer.org/cancer/bladder-cancer.html

About Hexvix®/Cysview® (hexaminolevulinate HCl)

Hexvix®/Cysview® is a drug that preferentially accumulates in cancer cells in the bladder making them glow bright pink during Blue Light Cystoscopy (BLC™). BLC™ with Hexvix® /Cysview® improves the detection of tumors and leads to more complete resection, fewer residual tumors and better management decisions.

Cysview is the tradename in the U.S. and Canada, Hexvix is the tradename in all other markets. Photocure is commercializing Cysview/Hexvix directly in the U.S. and Europe, and has strategic partnerships for the commercialization of Hexvix/Cysview in China, Canada, Chile, Australia and New Zealand. Please refer to https://photocure.com/partnering-with-photocure/our-partners/ for further information on our commercial partners.

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com, www.cysview.com

For further information, please contact:

Dan Schneider

President and CEO

Photocure ASA

Tel: + 1-609 759-6515

Email: ds@photocure.com

Erik Dahl

Chief Financial Officer

Tel: +47 450 55 000

Email: ed@photocure.no

David Moskowitz

Head of Investor Relations

Tel: +1 202 280 0888

Email: david.moskowitz@photocure.com

Media Enquiries:

Geir Bjørlo

Corporate Communications (Norway)

Tel: +47 91540000

Email: geir.bjorlo@corpcom.no

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/photocure/r/photocure-publishes-its-2020-esg-report,c3337220

Source URL - https://www.prnewswire.com/news-releases/photocure-publishes-its-2020-esg-report-301280978.html

WholisticResearch Acquires Domain of Adherex Technologies Inc.

Wed, 28 Apr 2021 12:09:43 +0600

WholisticResearch, the fact-finding blog on rare nootropics and peptides, announced today that it had acquired the domain name previously owned by Adherex Technologies Inc. biopharmaceutical company, committed to discover and develop therapeutics for cancer and cognitive improvement.

The CEO of WholisticResearch shared, "I believe that the domain of Adherex is a significant addition to our venture. This move can contribute to providing vendors and consumers with high-quality researched compounds synthesized in our UK labs."

This domain acquisition is a notable milestone for both companies as they share the same passion for providing a safer way to deal with cognitive issues and disorders. Together, WholisticResearch, combined with Adherex's promising scientific discoveries, more innovative and potent medical treatment is within our reach.

Since 2019, WholisticResearch has been providing the newest studies on brain-improving products. They analyze their effects and synthetic pathway to develop unfamiliar ideas and compounds.

WholisticResearch has gained trust from the vendors and readers. The company guides its vendors on how to improve their products, focusing on efficacy and cognitive enhancement. They also ensure their readers have the proper knowledge by thoroughly researched recommendations to improve their cognitive and mental performance.

Their products consist of small molecule peptides, multi-functionalized complexes, and most are plant-based modifications to guarantee safety.

WholisticResearch believes that cognitive improvement is not easy.

Founded in 1996 and traded stocks on the AMEX, Adherex Technologies, Inc. was a biotechnology company based in Ottawa that develops therapeutic drugs in line with its proprietary technology of cell adhesion platform.

Adherex developed solutions to unmet cancer and cognitive enhancement needs. Their main products are Eniluracil, ADH-1, and Sodium Thiosulfate (STS).

Exherin, one of their lead compounds, works by destroying the blood vessels that feed a cancerous tumor. It is proven to be effective by eliminating the tumor's food supply. With Adherex's cell adhesion platform, the compound has many potential applications, including drug administration through the skin.

Adherex's mission is to solve cancer patients' problems and offer multiple products to improve cognition. They have collaborated in the past with GlaxoSmithKline (GSK) for in-licensing Eniluracil and ADH-1. GlaxoSmithKline made a $3 million equity investment in Adherex and has sealed a deal with a potential maximum payment of around $220 million and additional sales royalties.

Besides GSK, Adherex also had an exclusive license agreement with Oregon Health & Science University for thiol-based compounds (including STS and NAC) and their oncology use.

Adherex maintains scientific publications highlighted in different journals such as The Journal of Biological Chemistry, Cancer and Metastasis Reviews, Inflammation, Molecular Membrane Biology, Molecular and Cellular Neuroscience, and Life Sciences.

After Scientific Breakthrough: Digid Seeks FDA Approval for Its Rapid Corona Antigen Test

Sat, 30 May 2020 07:10:09 +0600

At the high-security laboratory of the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany, the revolutionary Cantisense™ technology of the German health technology company Digital Diagnostics AG was used for the first time to successfully detect SARS-CoV-2 viruses in high measuring accuracy in test liquids.

In contrast to PCR testing, the new test provides a clear electronic "YES" or "NO" information within a few minutes, saving precious time in the diagnosis. What's more, the Digid Cantisense™ SARS-CoV-2 Test directly detects the presence of the virus while other rapid tests only recognize antibodies.

Konstantin Kloppstech, CTO at Digital Diagnostics, says: "Recent test series at the HZI high-security laboratory have shown that SARS-CoV-2 viruses can be detected directly using our Cantisense technology and without the need for PCR or further sample processing. This is a scientific breakthrough. We have coated cantilevers with a capture layer of highly specific monoclonal antibodies, which can reliably bind SARS-CO-2 viruses in the test fluid."

Constantin von Gersdorff, CEO of Digital Diagnostics, said: "The next step will be to initiate clinical studies with patient samples. To this end, we have already established international collaborations with leading hospitals."

With Digid's test kit, the measurement results are transmitted wirelessly from a sensor hub to a mobile device. By connecting to a secure analytics platform, the sensor data can be augmented with further data and processed anonymously for research and diagnostic applications.

Due to its measurement speed and the highly reliable results, the test is particularly suitable to support the containment of the current SARS-CoV-2 pandemic. The test offers the possibility of simple and rapid testing of patients and medical staff as an alternative to laboratory tests and enables reliable identification of infected persons within minutes. The possible areas of application therefore also include screening for access control at airports and railway stations, hospitals and specially protected areas (such as retirement homes) as well as for companies who want to ensure that their production runs smoothly and safely.

Digital Diagnostics has applied for approval of the Digid Cantisense™ SARS-CoV-2 Test by the US Food and Drug Administration (FDA). Digid aims to provide millions of units by July 2020. A further scaling of capacities is planned in the short term. The experts at Digital Diagnostics are also working at full speed to further develop the technology and to adapt the point-of-care testing procedure for use by consumers at home.

Source - https://www.newswire.com/news/after-scientific-breakthrough-digid-seeks-fda-approval-for-its-rapid-21153615

Las Vegas-Based Biopharmaceutical Company EUCYT Promotes Translational Cell Scientist Expert to Chief Scientific Officer

Fri, 22 May 2020 08:54:27 +0600

Biopharmaceutical company EUCYT announced Tammy C. Luttrell, MSPT, Ph.D., CWS, FCCWS, has been promoted to Chief Scientific Officer. Luttrell’s advancement follows her initial stint as Vice President of Product Development beginning last August.

The promotion also highlights EUCYT’s commitment to encouraging the need for more women to join science, technology, engineering and mathematics (STEM) careers.

“I’m truly blessed to be part of such a wonderful team here in Las Vegas. This is a fabulous opportunity for me personally and for our city and university partners,” said Luttrell. “With the EUCYT proprietary technology platform, we have the opportunity to truly bring bench science to the bedside and significantly improve the quality of life for patients and, at the same time, continue to push the forefront of applied science. Biological science will pave the way for continued improvement in medicine. It will allow me to focus even more intensely on the wonderful advancements our company is making in generative medicine and health. I also hope it shows just how much of a contribution women can make in STEM careers and encourage them to seek out such roles.”

Luttrell brings more than 30 years’ experience, in international regenerative medicine research, primarily in the trauma, burn and wound care space. As the Chief Scientific Officer, she will continue leading EUCYT’s important development of a potential treatment for COVID-19-positive patients called COVIXO.

COVIXO is a mesenchymal stem-cell-derived therapy that harnesses the power of the immune system to augment the body’s natural response to invading pathogens such as severe acute respiratory syndrome coronavirus 2, the causative agent behind COVID-19. For information visit: https://eucyt.com/wp-content/uploads/2020/03/covixo.pdf.

“This promotion shows just how important Dr. Luttrell’s contributions have been to a potential treatment for COVID-19 and the EUCYT team’s projects in general,” said Chief Executive Officer, Travis H. Bird. “She brings three decades of wound and burn care emphasis which is a perfect complement to the regenerative medicine work we’re doing to define the future of and heal patients, not just treat them.”

Luttrell’s extensive career includes helping revamp inner-city Las Vegas’ Sunrise Hospital and Medical Center’s RESTORE Wound Care Center/BRCA Burn Unit. She also is a physical therapy doctoral program adjunct faculty member at Colorado University in Denver and has owned her own consulting firm since 2000, where she handles special projects for the states of Colorado and Arkansas, including legal medical case reviews, wound center consultations and staff trainings. She also provides educational presentations and lectures domestically and internationally pertaining to wound healing and skin diseases.

About EUCYT

EUCYT is a biopharmaceutical company focusing on precision healthcare by harnessing the power within the human body to change the way people heal. EUCYT is committed to delivering safe, effective, leading-edge, advanced biologic technology.

Source - https://www.newswire.com/news/las-vegas-based-biopharmaceutical-company-eucyt-promotes-translational-21149053